يعرض 1 - 10 نتائج من 27 نتيجة بحث عن '"neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES]"', وقت الاستعلام: 1.00s تنقيح النتائج
  1. 1

    المساهمون: Institut Català de la Salut, [Yu EY] University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA. [Piulats JM] Catalan Institute of Oncology, Barcelona, Spain. [Gravis G] Institut Paoli Calmettes, Marseille, France. [Fong PCC] Auckland City Hospital, Auckland, New Zealand. University of Auckland, Auckland, New Zealand. [Todenhöfer T] Studienpraxis Urologie, Nürtingen, Germany. [Laguerre B] Centre Eugène Marquis, Rennes, France. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  2. 2

    المساهمون: Institut Català de la Salut, [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Alonso-Gordoa T] Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Mellado B] Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Méndez-Vidal MJ] Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain. Reina Sofía University Hospital (HURS), Córdoba, Spain. [Vázquez S] Lucus Augusti University Hospital, Lugo, Spain. [González-del-Alba A] Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain. [Morales-Barrera R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  3. 3

    المساهمون: Institut Català de la Salut, [Chi KN] BC Cancer Agency, Vancouver, Canada. [Barnicle A] Translational Medicine, AstraZeneca, Cambridge, United Kingdom. [Sibilla C, Corcoran C] Precision Medicine and Biosamples, AstraZeneca, Cambridge, United Kingdom. [Lai Z, Barrett JC] Translational Medicine, AstraZeneca, Waltham, Massachusetts. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  4. 4

    المساهمون: Institut Català de la Salut, [Dhital B] Biochemistry and Molecular Biology Department, Mayo Clinic, Rochester, USA. Urology Department, Mayo Clinic, Rochester, USA. Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, USA. [Santasusagna S, Kirthika P] Biochemistry and Molecular Biology Department, Mayo Clinic, Rochester, USA. Urology Department, Mayo Clinic, Rochester, USA. [Xu M, Li P] Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, USA. [Carceles-Cordon M] Urology Department, Mayo Clinic, Rochester, USA. [Malumbres M] Cell Division & Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Cancer Cell Cycle group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  5. 5

    المساهمون: Institut Català de la Salut, [Agarwal N] Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, USA. [Azad A] Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. [Shore ND] Department of Urology, Carolina Urologic Research Center, Myrtle Beach, USA. [Carles J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fay AP] PUCRS School of Medicine Grupo Oncoclínicas, Porto Alegre, Brazil. [Dunshee C] Urological Associates of Southern Arizona, Tucson, USA, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  6. 6

    المساهمون: Institut Català de la Salut, [Mucci LA] Harvard T.H. Chan School of Public Health, Boston, USA. [Vinson J, Gold T, Gerke T, Filipenko J, Green RM] Prostate Cancer Clinical Trials Consortium, New York, USA. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: BASE-Bielefeld Academic Search Engine
    Scientia

    وصف الملف: application/pdf

  7. 7

    المساهمون: Institut Català de la Salut, [Agarwal N] Huntsman Cancer Institute (NCI-CCC) at the University of Utah, Salt Lake City, UT, USA. [Azad A] Peter MacCallum Cancer Centre, Melbourne, Australia. [Shore ND] Carolina Urologic Research Center, Myrtle Beach, SC, USA. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Fay AP] PUCRS School of Medicine Grupo Oncoclínicas, Porto Alegre, Brazil. [Dunshee C] Urological Associates of Southern Arizona, Tucson, AZ, USA, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  8. 8

    المساهمون: Institut Català de la Salut, [Zurita AJ] The University of Texas MD Anderson Cancer Center, Houston, TX. [Graf RP, Raskina K, Sokol E, Jin D] Foundation Medicine Inc, Cambridge, MA. [Villacampa G, Casanova-Salas I, Vivancos A, Carles J, Mateo J] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  9. 9

    المساهمون: Institut Català de la Salut, [Wilson BE] Princess Margaret Cancer Centre, Toronto, Canada. Faculty of Medicine, University of New South Wales, Kensington, Australia. Kinghorn Cancer Centre, St Vincents Hospital, Darlinghurst, Sydney, Australia. [Armstrong AJ] Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA. [de Bono J] The Institute of Cancer Research and Royal Marsden Hospital, London, UK. [Sternberg CN] Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY 10021, USA. [Ryan CJ] Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA. [Scher HI] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  10. 10

    المساهمون: Institut Català de la Salut, [Joshua AM, Crumbaker M] Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, NSW, Australia. [Armstrong A] Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA. [Scher HI] Memorial Sloan Kettering Cancer Center, New York, NY, USA. [de Bono J] The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. [Tombal B] Cliniques Universitaires Saint-Luc, Brussels, Belgium. [Carles J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie

    المصدر: Scientia
    European Journal of Cancer, Vol. 170, p. 285-295 (2022)

    مصطلحات موضوعية: Male, Cancer Research, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Antineoplastic Agents, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Disease-Free Survival, Organic Chemicals::Amidines::Guanidines::Biguanides::Metformin [CHEMICALS AND DRUGS], Nitriles, Phenylthiohydantoin, Enzalutamide, Humans, Overall survival, Prospective Studies, Other subheadings::/therapeutic use [Other subheadings], Radiographic progression-free survival, Castration-resistant prostate cancer, Randomized Controlled Trials as Topic, Retrospective Studies, Otros calificadores::/uso terapéutico [Otros calificadores], compuestos orgánicos::amidinas::guanidinas::biguanidas::metformina [COMPUESTOS QUÍMICOS Y DROGAS], nutritional and metabolic diseases, Statin, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Pròstata - Càncer - Tractament, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant [DISEASES], Metformin, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Oncology, Metformina - Ús terapèutic, neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES], Benzamides, Avaluació de resultats (Assistència sanitària), Hydroxymethylglutaryl-CoA Reductase Inhibitors

    وصف الملف: application/pdf